Bispecific monoclonal antibodies that bind a tumor-associated antigen and CD3 on T cells to redirect cytotoxic T-cell activity against malignant cells.
Bispecific monoclonal antibodies that simultaneously bind CD3 on T cells and a tumor-associated antigen on malignant cells, crosslinking T cells to tumor targets to trigger CD3-mediated activation, immunologic synapse formation, and perforin/granzyme-mediated cytotoxic killing.
YES
DIRECT
CD20×CD3 bispecific antibodies bridge T cells to CD20+ cells, activating T cells via CD3 to form an immunologic synapse and kill the target cell through perforin/granzyme-mediated cytolysis and apoptosis.
Bispecific monoclonal antibodies that bind a tumor-associated antigen and CD3 on T cells to redirect cytotoxic T-cell activity against malignant cells.
Bispecific monoclonal antibodies that simultaneously bind CD3 on T cells and a tumor-associated antigen on malignant cells, crosslinking T cells to tumor targets to trigger CD3-mediated activation, immunologic synapse formation, and perforin/granzyme-mediated cytotoxic killing.
YES
DIRECT
The bispecific antibody binds GPRC5D on target cells and CD3 on T cells, crosslinking them to form an immunologic synapse and activate T-cell killing via perforin/granzyme-mediated apoptosis.
Afucosylated humanized IgG1 monoclonal antibody targeting IL‑5 receptor alpha (IL‑5Rα) on eosinophils and basophils; blocks IL‑5 signaling and induces ADCC to deplete eosinophils; used for severe eosinophilic asthma (brand: Fasenra).
Afucosylated humanized IgG1 monoclonal antibody against IL-5 receptor alpha on eosinophils and basophils; blocks IL-5 signaling and engages FcγRIIIa to induce potent ADCC, depleting eosinophils and reducing type 2 inflammation in severe eosinophilic asthma.
YES
DIRECT
Benralizumab binds IL-5Rα on eosinophils/basophils and engages FcγRIIIa on NK cells to drive potent antibody-dependent cellular cytotoxicity (ADCC), leading to apoptosis/depletion of IL-5Rα+ cells.
Afucosylated humanized IgG1 monoclonal antibody targeting IL‑5 receptor alpha (IL‑5Rα) on eosinophils and basophils; blocks IL‑5 signaling and induces ADCC to deplete eosinophils; used for severe eosinophilic asthma (brand: Fasenra).
Afucosylated humanized IgG1 monoclonal antibody against IL-5 receptor alpha on eosinophils and basophils; blocks IL-5 signaling and engages FcγRIIIa to induce potent ADCC, depleting eosinophils and reducing type 2 inflammation in severe eosinophilic asthma.
NO
INDIRECT
Benralizumab binds IL-5Rα on eosinophils/basophils; its afucosylated Fc engages FcγRIIIa (CD16a) on NK cells to trigger ADCC that kills IL-5Rα+ cells. CD16a+ cells act as effectors and are not depleted by the drug.
Human IgG1κ anti-CD38 monoclonal antibody (Darzalex) given IV post–allo-HCT after myeloablative TBI; targets CD38 on malignant lymphoblasts, inducing complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity/phagocytosis, and apoptosis, and depletes CD38+ immune subsets.
Human IgG1κ monoclonal antibody targeting CD38; binding to CD38 on tumor and immune cells triggers complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and can induce apoptosis, leading to depletion of CD38-expressing malignant cells and immunosuppressive subsets.
YES
DIRECT
Anti-CD38 IgG1 binds CD38 and induces complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) via Fc-engaged NK cells, antibody-dependent cellular phagocytosis (ADCP) by myeloid cells, and can trigger apoptosis of CD38+ cells.